CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is -208.8%, lower than 95% of its Biotechnology peers (median -24.5%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.67BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.20xvs all stocks
52-Week Change
739.35%vs all stocks
Market Capitalization
2.67BUSDvs all stocks (USD)
Enterprise Value
2.46BUSDvs all stocks (USD)
Forward P/E
-13.23xvs Biotechnology peers
Price to Book (MRQ)
22.82xvs Biotechnology peers
Enterprise to EBITDA
-11.23xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-49.05%vs Biotechnology peers
Return on Equity (TTM)
-208.80%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-219.17MUSDvs all stocks (USD)
Net Income (TTM)
-230.66MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-146.94MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-52.15MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-234.39MUSDvs all stocks (USD)
Pre-tax Income
-229.97MUSDFY2025 · Dec 31, 2025Net Income
-229.97MUSDFY2025 · Dec 31, 2025EBIT
-229.97MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-203.65MUSDFY2025 · Dec 31, 2025Research & Development
182.37MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
52.02MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
4.52MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
0.00USDFY2025 · Dec 31, 2025EPS (Basic)
-4.32USDFY2025 · Dec 31, 2025EPS (Diluted)
-4.32USDFY2025 · Dec 31, 2025Basic Shares Outstanding
53.21MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
53.21MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-229.97MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-147.80MUSDFY2025 · Dec 31, 2025Free Cash Flow
-148.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
216.05MUSDFY2025 · Dec 31, 2025Interest Paid
0.00USDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-229.97MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
26.32MUSDFY2025 · Dec 31, 2025Stock-based Compensation
58.86MUSDFY2025 · Dec 31, 2025Other Non-cash Items
20.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
8.07MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-11.11MUSDFY2025 · Dec 31, 2025Capital Expenditures
-506.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-506.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
172.96MUSDFY2025 · Dec 31, 2025Shares Outstanding
62.16MSharesUpdated Jul 19, 2026Float Shares
39.28MSharesUpdated Jul 19, 2026Shares Short
10.63MSharesUpdated Jul 19, 2026Short Ratio
11.72daysvs all stocks
Short % of Shares Outstanding
26.95%vs all stocks
% Held by Insiders
5.18%vs all stocks
% Held by Institutions
99.64%vs all stocks
Total Cash (MRQ)
169.53MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.71USDUpdated Jul 19, 2026Total Debt (MRQ)
55.99MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.4995xvs Biotechnology peers
Current Ratio (MRQ)
3.54xvs Biotechnology peers
Book Value per Share (MRQ)
1.81USDUpdated Jul 19, 2026Total Assets
351.53MUSDvs all stocks (USD)
Total Current Assets
214.82MUSDFY2025 · Dec 31, 2025Total Liabilities
194.15MUSDFY2025 · Dec 31, 2025Total Non-current Assets
136.72MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
148.62MUSDFY2025 · Dec 31, 2025Total Current Liabilities
45.53MUSDFY2025 · Dec 31, 2025Cash
2.28MUSDFY2025 · Dec 31, 2025Cash Equivalents
207.59MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
209.86MUSDFY2025 · Dec 31, 2025Accounts Payable
12.86MUSDFY2025 · Dec 31, 2025Short-term Debt
12.06MUSDFY2025 · Dec 31, 2025Long-term Debt
47.12MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
101.50MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.56BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
157.38MUSDvs all stocks (USD)
52-Week Low
5.00USDUpdated Jul 19, 202652-Week High
47.84USDUpdated Jul 19, 202652-Week Change
739.35%vs all stocks
Beta
2.20xvs all stocks
50-Day MA
37.14USDUpdated Jul 19, 2026200-Day MA
28.86USDUpdated Jul 19, 2026Avg 10-Day Volume
740.89KSharesUpdated Jul 19, 2026Avg 30-Day Volume
856.45KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-4.17USDUpdated Jul 19, 2026Other Income / Expense
-96.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -208.8%, lower than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: -2.09Industry median: -0.25Industry P5: -1.55Peers compared: 197
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 3.54Altman Z-Score: 0.46
Financial Health
Altman Z-Score 0.46: distress zoneCritical
Altman Z-Score: 0.46
Low earnings qualitySignificant
Earnings Quality Score: -0.56
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $2.67B, above the global median of $1.15BNotable
Market cap (USD): 2,668,344,724Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Maravai Lifesciences Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sinocelltech Group Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ligachem Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
MicroPort Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Double Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk